PCSK9 and peripheral arterial disease: Future prospective studies evaluating PAD in subjects with FH could provide valuable insights into their long-term cardiovascular outcomes and tailor strategies of novel lipid-lowering agents such as PCSK-9 inhibitors for treatment of these high-risk individuals, in particular in the context of improved life- expectancy.